CSIMarket
 
Iovance Biotherapeutics Inc   (NASDAQ: IOVA)
Other Ticker:  
 
 
Price: $3.2300 $-0.18 -5.279%
Day's High: $3.47 Week Perf: -1.22 %
Day's Low: $ 3.18 30 Day Perf: -13.64 %
Volume (M): 6,704 52 Wk High: $ 14.23
Volume (M$): $ 21,653 52 Wk Avg: $8.19
Open: $3.36 52 Wk Low: $2.70



 Market Capitalization (Millions $) 939
 Shares Outstanding (Millions) 291
 Employees 135
 Revenues (TTM) (Millions $) 164
 Net Income (TTM) (Millions $) -372
 Cash Flow (TTM) (Millions $) -59
 Capital Exp. (TTM) (Millions $) 11

Iovance Biotherapeutics Inc
Iovance Biotherapeutics Inc is a biotechnology company that specializes in developing and commercializing life-saving cell therapies. They focus on the development of tumor-infiltrating lymphocyte (TIL) therapies, which involve the extraction of a patient's own immune cells, expanding and activating them in the lab, and then infusing them back into the patient to target and fight cancer cells.

The company's TIL therapies have shown promising results in clinical trials, particularly in patients with advanced melanoma. Iovance Biotherapeutics aims to provide personalized cancer treatments using TIL therapies as a potential alternative to traditional approaches like chemotherapy.

They have a dedicated team of scientists, researchers, and clinicians who work towards advancing their TIL therapies and expanding their pipeline to target different types of cancer. Additionally, the company collaborates with various academic and industry partners to leverage cutting-edge technology and expertise in their research and development efforts.

Iovance Biotherapeutics Inc operates globally and is committed to improving the lives of cancer patients by delivering innovative cell therapies that harness the power of the immune system to fight cancer.


   Company Address: 825 Industrial Road, Suite 100 San Carlos 94070 CA
   Company Phone Number: 260-7120   Stock Exchange / Ticker: NASDAQ IOVA


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMGN   -3.04%    
BIIB        2.99% 
EXEL        3.4% 
GILD        0.88% 
HALO        1.04% 
STRO   -7.71%    
• View Complete Report
   



Shares

Iovance Biotherapeutics? Second Wave of Inducement Grants Aims to Accelerate Innovation Amidst Market Challenges

Published Fri, Feb 21 2025 10:15 PM UTC

In-depth Analysis: Navigating Strategic Growth and Market Realities in BiotechIovance Biotherapeutics, Inc. (NASDAQ: IOVA), a prominent player in the field of biotechnology, continues to forge ahead with its bold commitment to innovation despite facing a challenging market environment. On February 21, 2025, Iovance unveiled its latest strategic maneuver: the approval of indu...

Management Announcement

Iovance Biotherapeutics Executes Inducement Grants for Key Executives and Staff to Enhance Innovation Amidst Financial Challenges,

Published Wed, Feb 12 2025 10:30 PM UTC

In an effort to bolster innovation and maintain a competitive edge within the biotechnology sector, Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) has announced a series of inducement stock grants aimed at attracting and retaining talent in a challenging market environment. Notably, the company recently approved stock options and restricted stock units for the new Chief Commer...

Shares

Iovance Biotherapeutics Bolsters Innovation with Inducement Grants: A Bold Move in the Fight Against Cancer,

Published Fri, Jan 17 2025 10:00 PM UTC

On January 17, 2025, Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a company dedicated to the advancement of innovative treatments for cancer, announced a significant step in its growth strategy. In a press release, Iovance disclosed that it had granted inducement stock options that encompass a total of 224,550 shares of its common stock to forty-one newly hired non-executiv...

Shares

Navigating the Biotechnology Frontier: Iovance Biotherapeutics Fortifies Workforce Through Strategic Inducement Grants,

Published Fri, Dec 20 2024 10:00 PM UTC

for : Iovance Biotherapeutics Leverages Inducement Grants to Attract Talent Amid Tumultuous Biotech LandscapeIn the competitive sphere of biotechnology, the strategic maneuvering of talent acquisition is pivotal to innovation and growth. Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a company at the forefront of developing groundbreaking tumor infiltrating lymphocyte (TIL) ...

Stock Market Announcement

Iovance Biotherapeutics Continues to Invest in Growth with Inducement Stock Options for New Employees

Published Fri, Aug 16 2024 9:00 PM UTC


Iovance Biotherapeutics, a leading biotechnology company specializing in innovative cancer therapies, recently announced the approval of new stock options and restricted stock units for twenty-four non-executive employees. This strategic move comes as part of the company s ongoing commitment to expanding its team and driving future growth.
This latest development bu...







Iovance Biotherapeutics Inc's Segments
United States    98.74 % of total Revenue
Rest of world    1.26 % of total Revenue

  Iovance Biotherapeutics Inc Outlook

On February 27 2025 the Iovance Biotherapeutics Inc provided following guidance

nnIovance Biotherapeutics Inc. Reports Robust Financial Performance and Strategic Updates for Q4 and Full Year 2024nn

On February 27, 2025, Iovance Biotherapeutics Inc. announced its financial results and corporate developments for the fourth quarter and the entirety of 2024, showcasing a strong performance relative to their previous guidance.

In the fourth quarter of 2024, the company generated a total product revenue of $73.7 million. This impressive figure contributed to an annual revenue total of $164.1 million for the fiscal year 2024, landing at the upper threshold of their previously set guidance range of $160 million to $165 million.

Demand for Amtagvi (...





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com